PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY. (23rd June 2022) - Jabbour, E.; Martinelli, G.; Vignetti, M.; Kantarjian, H.; Gomez-Almaguer, D.; Minami, Y.; Dombret, H.; Hennessy, M.; Vorog, A.; Wang, B.; Ribera, J.-M.